Cayman Captopril-D3; Purity- Greater Than Or Equal To 99% Deutera

Captopril-d₃ is intended for use as an internal standard for the quantification of captopril (Item No. 15313) by GC- or LC-MS. Captopril is a first generation nonpeptidic ACE inhibitor (IC₅₀ = 6.3 nM) that was designed based on bradykinin-potentiating peptides isolated from the venom of B. jararaca, a pit viper native to Brazil. ^1,2,3 It does not exhibit a domain preference for binding either the C- or N-terminal active sites of the somatic form of ACE.¹ Acute and chronic administration of captopril reduces blood pressure in spontaneously hypertensive Wistar-Kyoto rats and does not induce hypotension in salt-repleted normotensive Wistar-Kyoto rats.⁴ Captopril is also a competitive and reversible inhibitor of leukotriene (LTA₄) hydrolase, which results in the disruption of LTB₄ synthesis with an IC₅₀ value of 14 μM.⁵

WARNING This product is not for human or veterinary use.